Table 2.
Risk of End-Stage Renal Disease, Mortality, Major Adverse Cardiovascular Event, and Heart Failure Association With DPP4i Therapy Compare Nonusersa
| Outcome | DPP4is |
With vs without DPP4i therapyb |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Users |
Nonusers (reference) |
Unadjusted |
Inverse weighted |
Inverse weighted and adjustedc |
Inverse weighted and adjustedd |
|||||||||
| No. of events | Person-year | Incidence ratee (95% CI) | No. of events | Person-year | Incidence ratee (95% CI) | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| ESRD | 233 | 1449.9 | 160.7 (142.9-180.8) | 1968 | 12329.7 | 159.6 (153.3-166.2) | 1.04 (0.91-1.19) | .59 | 0.87 (0.75-1.00) | .06 | 0.85 (0.73-0.99) | .03 | 0.81 (0.70-0.94) | .04 |
| Mortality | 97 | 2113.4 | 45.9 (37.8-55.7) | 3652 | 18188.5 | 200.8 (195.0-206.7) | 0.23 (0.19-0.28) | <.001 | 0.26 (0.21-0.31) | <.001 | 0.26 (0.22-0.32) | <.001 | 0.28 (0.23-0.34) | <.001 |
| MACE | 138 | 1852.8 | 74.5 (63.4-87.4) | 1239 | 15964.5 | 77.6 (73.6-81.9) | 0.98 (0.82-1.17) | .80 | 0.87 (0.72-1.05) | .16 | 0.89 (0.73-1.07) | .21 | 0.86 (0.71-1.04) | .11 |
| hHFf | 207 | 1644.7 | 125.9 (110.8-143.0) | 1627 | 14433.9 | 112.7 (107.7-118.0) | 1.15 (0.99-1.33) | .06 | 1.18 (1.02-1.37) | .03 | 1.19 (1.02-1.38) | .02 | 1.17 (1.01-1.36) | .13 |
a
DPP4i = dipeptidyl peptidase-4 inhibitor; ESRD = end-stage renal disease; hHF = hospitalized heart failure; HR = hazard ratio; MACE = major adverse cardiovascular event.
b
Cox proportional hazards models used to compare DPP4i therapy with non-DPP4i.
c
After adjustment for age, sex, chronic kidney disease, and advanced chronic kidney disease.
d
After adjustment for age, sex, chronic kidney disease, advanced chronic kidney disease, and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use.
e
Per 103 person-years.
f
Hospitalization for a primary diagnosis of heart failure.